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CASE REPORT Open Access
Mononeuritis multiplex as the first presentation
of refractory sarcoidosis responsive to etanercept
In?s Br?s Marques *, Gavin Giovannoni and Monica Marta
Abstract
Background: Several disorders may present with mononeuritis multiplex and the etiological diagnosis can be
challenging.
Case presentation: We report a 42 year-old female who presented with severe lower limb neuropathic pain,
asymmetric weakness and sensory impairment and was diagnosed with mononeuritis multiplex. Biopsy showed
a granulomatous vasculitic process with eosinophils, scarce granulomata and axonal neuropathy and granulomatosis
with poliangiitis was assumed. Steroids, cyclophosphamide, alemtuzumab, azathioprine, mycophenolate mofetil and
rituximab were used, all with transient and insufficient response. Skin biopsy performed in a further exacerbation
allowed sarcoidosis diagnosis. Infliximab and, later, adalimumab induced good clinical and laboratorial response, but
neutralizing antibodies developed to both drugs, so etanercept was tried with good clinical response.
Conclusions: To the best of our knowledge, this is the first report of sarcoidosis successfully treated with etanercept.
This drug may be considered in refractory sarcoidosis after other TNF-α inhibitors failure, having the advantage of not
being associated with neutralizing antibodies development.
Background
Mononeuritis multiplex (MM) can be a manifestation of
several disorders including infectious, inflammatory, neo-
plastic, toxic, metabolic and hereditary conditions, and the
etiological diagnosis may be challenging. Rarely, it can be
a presentation of sarcoidosis, an inflammatory multisys-
tem granulomatous disease that can involve any part of
the nervous system.
Peripheral neuropathy is an uncommon manifestation of
sarcoidosis patients and presents more frequently with
symmetric axonal sensorimotor polyneuropathy, however
other manifestations are described, including MM, multi-
focal motor neuropathy, Guillain-Barr? syndrome, polyradi-
culopathy, lumbosacral plexopathy, small fibre neuropathy
and multiple painful sensory mononeuropathies [1-7]. Re-
ports of initial presentation with MM are rare [3,8,9].
Sarcoid neuropathy treatment can also be challenging
and, in patients refractory to steroids and imunossupres-
sants, tumor necrosis factor alpha (TNF-α) inhibitors are
invaluable [10,11]. According to literature, infliximab and
adalimumab, which bind both soluble and membrane
bound TNF-α, seem to be more effective in sarcoidosis
than etanercept, which binds only to soluble TNF-α with
incomplete inhibition of TNF-α bioactivity [12,13].
We report a 42-year old female presenting with MM
who was eventually diagnosed with sarcoidosis. Tumor ne-
crosis factor alpha (TNF-α) inhibitors were used after steroid
and immunosuppressants failure. As neutralizing antibodies
(NAbs) against anti-TNF-α antibodies developed, etaner-
cept was tried with good clinical response.
This case illustrates how sarcoidosis diagnosis and
treatment can represent a challenge and is, to the best of
our knowledge, the first report of sarcoidosis successfully
treated with etanercept.
Case presentation
A 42 year-old Afro-Caribbean female presented with severe
pain in the lower limbs associated with distal weakness,
with progressive worsening during the previous week.
Her past medical history was remarkable for long-
standing pigmented skin nodules in limbs and torso, bi-
lateral breast implants ten years prior and giving birth to
her first child at 26 weeks three months before.
Neurological examination revealed tetraparesis (distal
upper limbs: grade 4+/5; proximal lower limbs: right =
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grade 4/5, left = 3/5; distal lower limbs: right = grade 3/5,
left = 2/5), absent ankle reflexes, indifferent plantar re-
flexes, reduced positional sense in left ankle and up to
right knee and reduced vibration and superficial pain
sense up to both knees. Physical examination identified
multiple hyperpigmented small nodules over the limbs
and trunk.
Investigations
Blood workup revealed normocytic anemia, thrombocy-
tosis and increased erythrocyte sedimentation rate (ESR)
(110 mm/h), C-reactive protein (CRP) (33 mg/L) and
angiotensin converting enzyme (ACE) (74 units/L). Bio-
chemistry including ionogram, calcium, renal and liver
function was unremarkable. Syphilis, hepatitis A, B and
C and Human Immunodeficiency Virus serologies were
negative. Autoimmune studies showed positive antinu-
clear antibodies (titre > 1/640, speckled pattern) and anti-
neutrophil cytoplasmic antibodies (ANCA) with an atypical
cytoplasmic-ANCA (c-ANCA) pattern, however without
myeloperoxidaseA (MPO) or proteinase 3 (PR3) specifi-
city. Antinuclear antibodies, antibodies against double
stranded DNA, antibodies against extractable nuclear anti-
gens, anti-cardiolipin antibodies and lupus anticoagulant
test were negative.
Cerebrospinal fluid showed hyperproteinorraquia
(500 mg/L), 5 leukocytes, normal glucose, increased ACE
(1.47 units/ml). Direct microscopy, acid-fast bacilli smear,
cultures, including mycobacterial culture, and Herpesvirus
family and Adenovirus DNA were negative.
Brain and spinal cord magnetic resonance imaging re-
vealed slight pachymeningeal thickening and enhancement
over the vertex. Chest, abdomen and pelvis computerized
tomography recognized left breast implant intracapsular
rupture and mildly enlarged bilateral axillary lymph nodes
only.
Nerve conduction studies identified patchy asymmet-
rical involvement of sensory nerves in upper and lower
limbs with axonal involvement (both sural and superfi-
cial peroneal nerves and left ulnar nerve) and minor de-
nervation in the muscles supplied by the affected nerves,
consistent with MM.
Dermatology team diagnosed the skin lesions as nodu-
lar prurigo.
Treatment, outcome and follow up
As pain and weakness significantly worsened during
the following two weeks and a provisional muscle and
nerve biopsy description suggested an inflammatory
process, a course of intravenous (iv) cyclophosphamide
(15 mg/kg) and oral prednisolone (1 mg/kg/d) were
started with marked strength improvement in the fol-
lowing days. Oral cyclophosphamide (150 mg/day) was
started two weeks later.
Final biopsy findings described a granulomatous vascu-
litic process associated with axonal neuropathy. Muscle
biopsy showed perivascular inflammation without fibrin-
oid necrosis and a cluster of cells resembling a loose non-
necrotic granuloma. Nerve biopsy revealed florid axonal
neuropathy with large and small myelinated fibers active
degeneration, dense inflammatory infiltrates including
several scattered eosinophils and aggregates of epithelioid
macrophages forming loose granulomata in perineurium
and endoneurium, without vessel fibrinoid necrosis. Skin
biopsy was unremarkable.
Granulomatosis with polyangiitis (GPA) was presumed as
histology identified eosinophils and poorly formed granu-
lomata. She was discharged on cyclophosphamide, anal-
gesia and prednisolone taper until 20 mg/day. Clinically
she was almost pain free, but suffered severe fatigue.
Within three months, she stopped medication against
medical recommendation and worsened in the following
eight weeks, with severe neuropathic pain and inability to
walk autonomously. Neurological examination revealed
grade 3/5 tetraparesis, lower limbs arreflexia and sensory
gait ataxia. Inflammatory markers were increased (ESR =
86 mm/h; CRP = 54 mg/L). Cyclophosphamide (150 mg/
day) and prednisolone (40 mg/day) were restarted with
clinical and laboratorial improvement within one month.
Nevertheless, recurrence of severe symptoms occurred
two months later and alemtuzumab (20 mg/day, iv, 5 days)
was used with only mild improvement within three weeks.
By this time, 150 mg/day azatioprine (AZA) was associ-
ated with prednisolone taper, but worsening occurred on
every taper attempt. Whole body PET performed during
an exacerbation with severe systemic symptoms excluded
other areas of inflammatory activity and neoplasms.
After four months of AZA, slow clinical recovery was
reported. Stability was achieved for further six months
on prednisolone (17,5 mg/20 mg on alternate days) and
AZA (175 mg/day). However, severe pain and weakness
worsening followed and AZA was switched to mycophe-
nolate mofetil (MMF) (750 mg bd). At that point, breast
implants were removed as bilateral breast tumefaction
and a large left axillary adenopathy were noticed. Biopsy
showed granulomatous lymphadenitis and patchy stromal
fibrosis of breast tissue with periaqueductal and perilobu-
lar inflammation including occasional poorly formed non-
necrotizing granulomas, without signs of malignancy and
with negative acid-fast bacilli and fungi stains.
After four months of stability, neurological symptoms
recurrence associated with bilateral uveitis were treated
with iv methylprednisolone (1 g, 3 days). Oral prednisol-
one (40/60 mg on alternate days) and MMF (1 g, bd)
were increased. Four rituximab infusions (375 mg/m2/
week) were performed. Despite improvement of systemic
symptoms and inflammatory markers, marked disability
persisted due to pain and weakness.
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Skin biopsy obtained three months later, during a
period of skin lesions exacerbation, showed numerous
granulomata in the dermis with perivascular lymphocytic
infiltrates, without vasculitic features. This time the clin-
ical and histopathological features suggested sarcoidosis,
so our treatment strategy changed.
Infliximab (3 mg/kg, iv, at 0/2/6 weeks and every 6 weeks
thereafter) was started in combination with MMF and
prednisolone with excellent prompt clinical and laborator-
ial response. Coinciding with clinical symptoms recur-
rence, five months later, NAbs againts infliximab were
detected. Switch to adalimumab (40 mg, sc, every second
week) maintained improvement, however, despite strength
improvement, sensory ataxia and neuropathic pain still
hindered autonomous walking. Eight months later, an-
other period of treatment efficacy loss followed, associated
with NAbs against adalimumab, reducing the choice of
TNF-α inhibitors described as beneficial in sarcoidosis.
We eventually chose etanercept (50 mg, sc, once a week)
still in combination with MMF (1.5 g/day) and prednisol-
one (40 mg/60 mg on alternate days) which controlled
most clinical symptoms with complete motor and cogni-
tive functional recovery. She remains clinically stable
after eighteen months on etanercept, presenting full
power with fatigability, fluctuant facial asymmetry, marked
sensory gait ataxia, areas of sensory deficits with numb-
ness and dysesthesia, absent reflexes in the lower limbs
and decreased reflexes in the upper limbs. Despite clinical
stability, inflammatory markers remain increased (ESR =
83 mm/h; CRP = 14 mg/L) and skin lesions persist.
Figure 1 represents clinical symptoms and inflammatory
markers evolution during the disease course and the treat-
ments performed during this period.
Discussion
Sarcoid neuropathy is a rare manifestation of sarcoidosis,
estimated to occur in 15% of cases [14]. Theories to ex-
plain sarcoid neuropathy include ischemic axonal degen-
eration and demyelination resulting from local pressure
provoked by epineural and perineural granulomas and
granulomatous vasculitis; axonal and myelin damage by
proteolytic enzymes secreted by epithelioid cells; and is-
chemic nerve lesions resultant vessel fibrinoid necrosis
[3]. Diagnosis requires histological demonstration of non-
caseating granulomas, preferably in biopsy tissue obtained
from other organs involved, reserving nerve biopsy for
Figure 1 Clinical and inflammatory markers evolution during the course of the disease and treatments performed during this period.
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patients without other accessible organs affected. As
no histological features differentiate sarcoid granulomas,
other granulomatous diseases must be excluded, most im-
portantly acid-fast bacilli and fungi infections. In the case
of our patient, MM associated with ANCA antibodies and
granulomatous vasculitic process suggested a systemic
vasculitis, possibly GPA or Churg-Strauss syndrome (CSS).
Despite disparate manifestations, these conditions can
present with MM before evident systemic features
emerge [15,16]. Histologically, GPA usually shows vas-
culitis and/or necrotizing granulomas and CSS char-
acteristically reveals eosinophilic infiltrates, vasculitis and
granulomas with eosinophilic necrosis [17]. GPA usually
associates with c-ANCA PR3 specific and CSS with
p-ANCA MPO specific [17]. Atypical ANCA occur in
various disorders, including systemic immune-mediated
diseases and infections [17]. In our patient, atypical
ANCA without PR3/MPO specificity and absence of
necrotizing granulomas were uncharacteristic for systemic
granulomatous vasculitis.
Infectious granulomatous diseases that may present with
MM were also considered in the differential diagnosis. Tu-
berculoid Leprosy (TL), caused by Mycobacterium leprae,
usually involves the skin and the peripheral nerves in an
asymmetrical pattern and may present as MM [18-20],
however the skin lesions are usually anesthetic and present
as hypopigmented macules or erythematous plaques with
well-defined elevated borders and an atrophic center, and
peripheral nerves are usually tender and thickened, making
this diagnosis less likely in our patient. TB can also very
rarely present with peripheral neuropathy, but usually re-
sults from nerve or root compression by regional tubercu-
lar lymphadenitis, vertebral collapse or abscess, without
direct invasion of the peripheral nerves by the necrotizing
granulomas [21-23]. The nerve biopsy of our patient
showed dense inflammatory infiltrate in all nerve compart-
ments with granulomata in the perineurium and endo-
neurium, findings not expected in TB. The negative stains
for acid-fast bacilli and mycobacterial cultures were also
not suggestive of these granulomatous infections.
The recently described Autoimmune/Inflammatory
Syndrome Induced by Adjuvants (ASIA) [24], includes
immune mediated diseases triggered by an adjuvant stimu-
lus. It results from exposure to external stimuli, including
infectious agents, vaccines, silicone, aluminium salts
and others, that are thought to stimulate the immune
system and trigger an immune response in persons
with a favourable genetic background. The most fre-
quently reported symptoms are myalgia, arthralgia, fa-
tigue, sleep disturbances, fever, cognitive impairment and
other neurological manifestations, especially associated
with demyelination, and this symptoms are thought to im-
prove with removal of the inciting agent [24,25]. As our
patient had breast implants, ASIA was considered in the
differential diagnosis, however the clinical manifestations
were not the most typical of this syndrome and the disease
exacerbations continued after surgical removal of the
breast implants.
Sarcoid neuropathy early treatment with oral prednisol-
one (1 mg/kg/day) or iv methylprednisolone (0.5-1 g/day)
is recommended and steroid-sparing medications, such as
AZA or MMF, must be considered. In refractory patients,
TNF-α inhibitors, mostly infliximab are proposed [26], as
TNF-α is thought to be involved in antigen-driven, cell-
mediated responses and in granuloma formation. Mono-
clonal antibodies, infliximab and adalimumab, bind both
soluble and membrane bound TNF-α, whereas etanercept
binds only soluble TNF-α [13]. Reports of TNF-α in-
hibitors induced sarcoidosis [27], paradoxically describe
etanercept as being more commonly associated with granu-
loma development [28], possibly because of incomplete
TNF-α blockage. NAbs usually reduce anti-TNF-α anti-
bodies efficacy [29], and immunossupressants are sug-
gested to reduce antibody development risk, however our
patient developed NAbs despite concomitant MMF. Anti-
bodies to etanercept are usually non-neutralizing and do
not affect efficacy or safety [30].
In the case of our patient, steroids, cyclophosphamide,
alemtuzumab, azathioprine, mycophenolate mofetil and
rituximab were used, all with transient and insufficient
response. Alemtuzumab was used for presumed granulo-
matosis with polyangiitis, before sarcoidosis diagnosis, as
it has shown benefit in ANCA-associated refractory vas-
culitis [31] and clinical trials are ongoing to show evi-
dence. Despite good clinical and laboratorial response
was achieved with infliximab and, later, adalimumab,
neutralizing antibodies developed to both drugs, so eta-
nercept was tried with good clinical response.
To the best of our knowledge, this is the first re-
port of sarcoidosis responding to etanercept. In our
patient, despite significant clinical improvement, in-
flammatory markers, especially ESR, remain increased.
The lack of alternatives with proven efficacy and the rea-
sonable clinical stability achieved support our decision to
maintain this treatment.
Conclusions
Mononeuritis multiplex is a rare presentation of sarcoid-
osis with rare cases described in the literature. The differ-
ential diagnosis is extensive and biopsy of the nerve, or
other affected organ, is crucial for diagnosis. In refractory
patients, TNF-α inhibitors are invaluable, with many suc-
cessful cases of sarcoidosis treatment with infliximab and
adalimumab reported in the literature. This article presents
the first report of sarcoidosis treated with etanercept, add-
ing this drug as an option for refractory patients who failed
other TNF-α inhibitors, having the advantage of not being
associated with development of neutralizing antibodies.
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Learning points/take home messages
 Mononeuritis multiplex may be a presentation of
sarcoidosis,
 Sarcoidosis diagnosis requires histological demonstration
of non-caseating granulomas, preferably in biopsy
tissue obtained from organs involved outside of the
nervous system,
 TNF-α inhibitors, mostly infliximab and adalimumab,
are reported as efficacious in refractory cases,
 Etanercept may be an option in patients who failed
other TNF-α inhibitors, having the advantage of not
being associated with development of neutralizing
antibodies.
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